Progress in Alzheimer’s and Parkinson’s DiseasesAbraham Fisher, Israel Hanin, Mitsuo Yoshinda Springer Science & Business Media, 6 дек. 2012 г. - Всего страниц: 888 This book represents the fourth ina series of international conferences related to Alzheimer's (AD) and Parkinson's (PO) diseases. The first one took place in EHat, Israel in 1985; the second in Kyoto, Japan, in 1989; and the third in Chicago, IL, USA in 1993. This book incorporates the proceedings of the Fourth International Conference on Pro gress in Alzheimer's and Parkinson's Diseases, held in EHat, Israel, on May 18-23, 1997. This Conference was the 41st in the series of annual OHOLO Conferences sponsored by the Israel Institute for Biological Research (IIBR). It was also conducted under the aus pices of the Alzheimer's Association Ronald and Nancy Reagan Research Institute, USA. The Conference was attended by 550 participants from 28 countries, representing a broad spectrum of research interests; and included a well-balanced representation from aca demia, clinical institutions and pharmaceutical industry. The four-and-one-half day meeting served as an excellent medium for surveying the current preclinical and clinical develop ments in AD, PO, and other related disorders. The scientific program was divided into 24 oral sessions and daily poster sessions. The conference culminated in a round table discus sion. There were 122 talks and 161 posters. This book incorporates a combination of both. |
Содержание
3 | |
13 | |
25 | |
31 | |
39 | |
53 | |
59 | |
67 | |
Nicotinic Receptors as a New Target for Treatment of Alzheimers Disease | 463 |
S 120242 a Cognitive Enhancer Interacts with Nicotinic Neurotransmission | 469 |
Lewy Body Influence on Tacrine Efficacy | 477 |
Tacrine Treatment in Parkinsons Disease Dementia | 481 |
APP Localization and Trafficking in the Central Nervous System | 487 |
The Cholinergic but Not the Serotonergic Phenotype of a New Neuronal Cell | 495 |
The Molecular Basis Underlying the Discrete Activation of Signal Transduction | 503 |
Muscarinic Modulation of BAmyloid Precursor Protein ẞAPP Processing | 509 |
Neuronal Oxidative Stress Is a Common Feature of Alzheimers and Parkinsons | 77 |
Intracerebroventricular Administration of BetaAmyloid Peptide 2535 | 89 |
Molecular Characterization of the Neuroprotective Activity of Salicylates | 99 |
AgeRelated NaKATPase mRNA Expression and Alzheimers Disease | 113 |
HBGAM a Novel Amyloid Associated Protein Is Present in Prion Related | 121 |
Regulation of APP Metabolism by Protein Phosphorylation | 133 |
Identification of Peptides Binding to Presenilin 1 by Screening of Random | 141 |
Modulation by TNFa | 149 |
Direct Evidence that Lactate Is an Obligatory Aerobic Energy Substrate | 171 |
Comparative Study of Antioxidants Action on MembraneBound | 177 |
Amyloidẞ Hypothesis of Alzheimers Disease | 187 |
Anthracyclines and Amyloidosis | 197 |
The Amino Terminus of the BAmyloid Peptide Contains an Essential Epitope | 205 |
Animal Models of Amyloid Aggregation and Deposition | 213 |
The Conformations of Tau Protein and Its Aggregation into Alzheimer Paired | 222 |
Role of Neurofibrillary Degeneration in Alzheimers Disease | 235 |
Cytoskeletal Protein Gene Expression after Neuronal Injury Recapitulates | 241 |
Hyperphosphorylation of Tau in Apolipoprotein EDeficient Mice | 251 |
Aẞ Induces Cell Death in PC12 Cells and TauTransfected Cho Cells but Only | 257 |
Different Cognitive Profiles on Memory Tests in Parkinsons Disease | 265 |
Neuropsychological Subtypes and Rate of Progression in Alzheimers Disease | 271 |
Insulin Insulin Receptors and IgfI Receptors in PostMortem Human Brain | 287 |
Demonstration of Aluminum in the Brain of Patients with Alzheimers Disease | 293 |
Lipid Composition of Different Brain Regions in Patients with Alzheimers | 301 |
Release from Proactive | 309 |
Cognitive and NonCognitive Symptoms in Senile Dementia | 317 |
Dementia Associated Sleep Disorders | 323 |
Cognitive Impairment in Patients with Parkinsonism | 337 |
Case Report on a Generalized Epilepsy in a Patient Suffering from Parkinsons | 359 |
Effects of Progressive Neurological Disease on Interpersonal Relations between | 371 |
Cognitive Deficits in Alzheimers Disease Parkinsons Disease | 377 |
Recall of Ytzhak Rabins Assassination by Demented People | 385 |
Genetic Aspects of Parkinsons Disease | 393 |
A Chromosome 6qLinked Parkinsonism | 401 |
Cytokines in Parkinsons Disease | 407 |
NMethylRSalsolinol and RSalsolinol NMethyltransferase as Possible | 413 |
Antioxidant and Cytoprotective Properties of Apomorphine | 421 |
Toxicity of 1BnTIQ Endogenous Amine in the Brain in Mesencephalic Slice | 429 |
Motor Fluctuation and Levodopa Absorption | 439 |
The Rationale for Development of Cholinergic Therapies in AD | 445 |
A New Avenue for Research into Neurobiological | 451 |
Crystallographic Studies on Complexes of Acetylcholinesterase with the Natural | 523 |
What Can Be Learned from the Use of HuAChE Mutants for Evaluation | 531 |
Pharmacological and Transfection Studies | 541 |
The NonCatalytic Role and Complex Management of Acetylcholinesterase | 551 |
Antisense Oligodeoxynucleotide Dependent Suppression | 557 |
Tacrine Reduces the Secretion of Soluble Amyloid BetaPeptides in | 563 |
Do They Work? | 571 |
The Preclinical Pharmacology of Metrifonate a LongActing and Well Tolerated | 579 |
Increase in Cerebral Blood Flow and Glucose Utilization in Beneficial Effect | 587 |
QuaternaryLipophilic Carbamates with Blood Brain Barrier Permeability | 595 |
Characterization of C10 Substituted Analogues of Huperzine A as Inhibitors | 601 |
Development and Uses of Small Molecule Ligands of TrkA Receptors | 615 |
Molecular Cloning Transient Expression and Neurotrophic Effect for | 627 |
PeptideMediated Neuroprotection | 635 |
Gene Therapy of a Rodent Model of Parkinsons Disease Using | 647 |
Memory Enhancing | 653 |
Age Dependence of Muscarinic Plasticity in the Rat Hippocampus | 661 |
AF64A and 192IgGSaporin | 667 |
Molecular Mechanisms of AF64A Toxicity in the Cholinergic Neuron | 675 |
Role of Nitric Oxide | 681 |
Effect of AF64ANGF Treatment on ChAT mRNA Expression in | 687 |
Induction Secretion and Pharmacological Regulation of BAPP in Animal | 695 |
In Vivo Neurotoxicity of BAmyloid 140 in the Rat Hippocampus | 705 |
Interval Hypoxic Training Prevents Oxidative Stress in Striatum and Locomotor | 717 |
An a₂Adrenoceptor Agonist Clonidine Disrupts Attentional Performance | 725 |
Functional Neuroimaging Reveals Decline from Premorbid Functioning in AD | 733 |
Affinity to Monoamine Transporters in Rat Forebrain | 739 |
A Peripheral Marker of Alzheimers Disease | 747 |
alAntichymotrypsin and Apolipoprotein E Polymorphism in Alzheimers | 757 |
Influence of the APOE Genoptype on Serum ApoE Levels in Alzheimers | 765 |
Development of a Specific Diagnostic Test for Measurement of BAmyloid | 773 |
Indices of Oxidative Stress in the Peripheral Blood of de Novo Patients with | 779 |
Acylphosphatase Levels in Alzheimers Disease Cultured Skin Fibroblasts | 787 |
APOE GenotypeRelated Blood Pressure in Senile Dementia | 799 |
Changes in Cerebral Blood Flow Associated with Disease Staging and APOE | 811 |
A Simple Procedure of Immunochemical Detection of Amyloid ẞ Proteins Using | 823 |
Finding the Optimal Dose for Efficacy | 829 |
Trial to Prevent Neurodegeneration in Persons Genetically Predisposed | 841 |
Current Neurotransmitter Strategies in AD Drug Development | 851 |
Harmonization of Drug Approval Guidelines in Alzheimers and Parkinsons | 860 |
Другие издания - Просмотреть все
Progress in Alzheimer’s and Parkinson’s Diseases Abraham Fisher,Israel Hanin,Mitsuo Yoshinda Ограниченный просмотр - 1998 |
Progress in Alzheimer’s and Parkinson’s Diseases Abraham Fisher,Israel Hanin,Mitsuo Yoshinda Недоступно для просмотра - 2011 |
Progress in Alzheimer’s and Parkinson’s Diseases Abraham Fisher,Israel Hanin,Mitsuo Yoshinda Недоступно для просмотра - 2012 |
Часто встречающиеся слова и выражения
Acad acetylcholine acetylcholinesterase AChE acid activity agonists allele Alzheimer disease Alzheimer's and Parkinson's Alzheimer's disease amyloid amyloid precursor protein antibodies antioxidant apolipoprotein apoptosis Aẞ associated binding Biochem Biol Brain Res Cacabelos cell death cerebral Chem choline cholinergic cholinesterase clinical cognitive impairment cortex cortical cultures cybrids decrease deficits dementia disorders dopamine dopaminergic dose drug edited by Fisher effects enzyme Figure function gene genetic genotype hippocampus human huperzine increased induced inhibition inhibitors interaction isoforms lesions levels levodopa Lewy body lipid membrane memory metabolism metrifonate mg/kg mice molecular mRNA muscarinic mutations Natl Neurochem neurodegenerative Neurology neurons Neurosci neurotoxicity nicotinic NM(R)Sal normal Parkinson's disease Parkinson's Diseases edited pathology peptide phosphorylation plaques Plenum Press presenilin Proc Progress in Alzheimer's receptor reduced role ẞ-amyloid striatum studies substantia nigra tacrine tau protein therapy tion tissue treatment vitro vivo